Avidity
Joseph Johnston has a strong background in regulatory affairs and quality, with extensive experience in the biopharmaceutical industry. Joseph is currently serving as the Senior Vice President of Regulatory Affairs & Quality at Avidity Biosciences, Inc., a company focused on developing innovative oligonucleotide-based therapies for serious diseases. Prior to their role at Avidity Biosciences, Joseph held the same position at Catabasis Pharmaceuticals, Inc. from 2016 to 2021. Before that, they worked as the Vice President of Regulatory Affairs and Quality at Ionis Pharmaceuticals, Inc. from 2008 to 2016.
Joseph Johnston has a Master of Science (M.Sc.) degree in Pharmacology from the University of Pennsylvania. Joseph also has an Executive MBA from the University of California, Irvine - The Paul Merage School of Business. In addition, they hold a Bachelor of Arts (B.A.) degree in Biology from the University of Pennsylvania. No specific start or end years are provided for any of these educational experiences.
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.